OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function
/PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces...
Israel General Comunidad Autonoma De Cataluna Noord Holland Elisabeth Lindner Gema Ariceta European Society Of Pediatric Nephrology
Source: prnewswire.com